US 12,257,215 B2
Mirdametinib treatment
Uchenna H. Iloeje, Stamford, CT (US); Abraham J. Langseth, Stamford, CT (US); and Todd Webster Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics, Inc., Stamford, CT (US)
Filed on May 24, 2024, as Appl. No. 18/674,168.
Application 18/674,168 is a continuation of application No. 18/518,127, filed on Nov. 22, 2023.
Application 18/518,127 is a continuation of application No. 18/334,518, filed on Jun. 14, 2023, granted, now 11,883,375, issued on Jan. 30, 2024.
Application 18/334,518 is a continuation of application No. 18/185,148, filed on Mar. 16, 2023, granted, now 11,806,322, issued on Nov. 7, 2023.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2024/0307329 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/166 (2006.01); A61K 9/00 (2006.01); A61K 31/216 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61K 31/216 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)] 22 Claims
 
1. A method of treating a human patient diagnosed with neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient wherein (a) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is administered 2 mg mirdametinib twice daily, or (b) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is administered 3 mg mirdametinib twice daily.